Allied Market Research
Loading...
0
New
New
2021
Pneumonia Therapeutics Market

Pneumonia Therapeutics Market by Therapeutics (Prevention Vaccines and Treatment Drugs), Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), and Age Group (Pediatric, Adult, and Geriatric): Global Opportunity Analysis and Industry Forecast, 2021–2030

A11230
Pages: 208
Aug 2021 | 530 Views
   
Author(s) : : Apoorva Srivastava , Onkar Sumant
Tables: 120
Charts: 46
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pneumonia Therapeutics Market

Request Now !

Pneumonia Therapeutics Market Overview:

The global pneumonia therapeutics market size was valued at $12,293.9 million in 2020, and is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030. Pneumonia therapeutics are used for prevention and treatment of patients suffering from pneumonia. Pneumonia is an infection that causes inflammation in individuals’ lungs, especially the alveoli. The alveoli gets filled up with fluid or pus. The symptoms in an individual affected with pneumonia include fever, chills, cough, and trouble in breathing. Furthermore, other common causes of viral pneumonia include respiratory syncytial virus (RSV), influenza, and SARS-CoV-2. In addition, commonly observed cause of bacterial pneumonia is Streptococcus pneumoniae (pneumococcus). 

COVID-19 has positively impacted the pneumonia therapeutics market, owing to the growth in demand for COVID-19 associated pneumonia. and surge in incidences of pneumonia cases during the commenced period.

Surge in incidence of pneumonia is expected to propel the growth of the pneumonia therapeutics market during the forecast period. Furthermore, rise in prevalence of community-acquired pneumonia, especially in younger individuals is expected to fuel the growth of the market in the coming years. In addition, increase in prevalence demonstrates unmet clinical needs, which propels the demand for pneumonia therapeutics in the coming years. In addition, surge in R&D related to the treatment methods is expected to drive the market growth. However, lack of awareness regarding preventive vaccines is expected to hinder the growth of the market. On the contrary, surge in investments in the development of newer products that can be used as therapeutics for pneumonia is anticipated to create remunerative opportunities for the expansion of the pneumonia therapeutics market during the forecast period.

Pneumonia-Therapeutics-Market

Get more information on this report : Request Sample Pages

The World Health Organization on January 30, 2021 declared COVID-19 outbreak a public health emergency of international concern. Individual suffering COVID-19 is highly susceptible to pneumonia, thus causing shortness of breath and filling of mucus in the alveoli. This is expected to propel the growth of pneumonia therapeutics market. In addition, increase in R&D for the treatment of COVID-19-associated pneumonia is expected aid the market to generate high revenue during the forecast period. However, dearth of workforce as well as resource limitations due to COVID-19 are expected to negatively impact the growth of the industry in the forecast period. In addition, implementation of stringent government regulations regarding the lockdown has declined the market growth. Moreover, the need of the hour is to bring up newer products that can help combat with COVID-19. This helps the pneumonia therapeutics market to generate higher revenue during the forecast period.

Global Pneumonia Therapeutics Market Segmentation  

The global pneumonia therapeutics market is segmented into therapeutics, distribution channel, age group, and region. On the basis of therapeutics, the market is categorized into prevention vaccines and treatment drugs. By distribution channel, it is classified into hospitals, pharmaceutical stores, and others. Depending on age group, it is categorized into pediatric, adult, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Segment review 

On the basis of therapeutics, the treatment drugs segment is expected to garner highest revenue during the forecast period, owing to rise in incidence of pneumonia. Furthermore, surge in demand for novel drugs among individuals suffering from pneumonia notably contributes toward the market growth. In addition, advent of resistant strains has boosted the need for R&D of vaccines, which is expected to help the segment generate higher revenue during the forecast period.

Pneumonia Therapeutics Market
By Therapeutics

Your browser does not support the canvas element.

The Prevention Vaccines segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

Depending on distribution channel, the hospitals segment is anticipated to dominate the market during the forecast period, owing to the availability of skilled professionals for the treatment of pneumonia and surge in number of outpatients and inpatients preferring hospitals. In addition, higher investment of hospitals for adopting novel pneumonia therapeutics methods for civil population is anticipated to propel the growth of hospital segment during the forecast period. Furthermore, rise in adoption of novel and efficient drugs for pneumonia treatment fosters the pneumonia therapeutics market growth. 

Pneumonia Therapeutics Market
By Distribution Channel

Your browser does not support the canvas element.

The Hospitals segment is expected to lead the market throughout the forecast period.

Get more information on this report : Request Sample Pages

By age group, the geriatric segment led the global pneumonia therapeutics market in 2020, and is expected to continue this trend in the coming years. This is attributed to surge in geriatric population worldwide. Furthermore, susceptibility to develop age-associated diseases contributes toward the growth of the segment. However, the pediatric segment is expected to gain significant revenue shares, owing to the weaker immune system of the pediatric population and multidrug resistance observed. 

Pneumonia Therapeutics Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America segment held a highest revenue share in 2020, furthermore Asia-Pacific is expected to register the fastest CAGR during the forecast period.

Get more information on this report : Request Sample Pages

The key players profiled in this report include Abbott Laboratories, Bayer AG, Eli Lilly & Company, Glaxosmithkline PLC., Lupin Pharmaceuticals, Inc., Merck KGAA, Novartis AG, Pfizer, Inc., Sanofi S.A., and Teva Pharmaceuticals Industries Limited.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the pneumonia therapeutics market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • The report covers the pneumonia therapeutics market analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of factors that drive and restrain the growth of the pneumonia therapeutics market is provided. 
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and pneumonia therapeutics market growth.

Key Market Segments

By Therapeutics

  • Prevention Vaccines
  • Treatment Drugs

By Distribution Channel 

  • Hospitals 
  • Pharmaceutical Stores
  • Others

By Age Group

  • Pediatric
  • Adult
  • Geriatric

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of pneumonia
3.5.1.2.Upsurge in geriatric population with weaker immune systems
3.5.1.3.Increase in incidence and spending for community-acquired pneumonia
3.5.1.4.Surge in number of product launches

3.5.2.Restraint

3.5.2.1.High price of pneumonia therapeutics

3.5.3.Opportunity

3.5.3.1.Outbreak of novel viruses attacking respiratory system

3.5.4.Impact analysis

3.6.COVID-19 Impact analysis on the pneumonia therapeutics market

CHAPTER 4:PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS

4.1.Overview

4.1.1.Market size and forecast

4.2.Prevention vaccines

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.2.4.Market analysis, by distribution channel

4.3.Treatment drugs

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
4.3.4.Market analysis, by distribution channel

CHAPTER 5:PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospitals

5.2.1.Market size and forecast
5.2.2.Market analysis, by country

5.3.Pharmaceutical stores

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

5.4.Others

5.4.1.Market size and forecast
5.4.2.Market analysis, by country

CHAPTER 6:PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP

6.1.Overview

6.1.1.Market size and forecast

6.2.Pediatric

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Adult

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Geriatric

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:PNEUMONIA THERAPEUTICS MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. pneumonia therapeutics market, by therapeutics
7.2.2.1.2.U.S. pneumonia therapeutics market, by distribution channel
7.2.2.1.3.U.S. pneumonia therapeutics market, by age group

7.2.2.2.Canada

7.2.2.2.1.Canada pneumonia therapeutics market, by therapeutics
7.2.2.2.2.Canada pneumonia therapeutics market, by distribution channel
7.2.2.2.3.Canada pneumonia therapeutics market, by age group

7.2.2.3.Mexico

7.2.2.3.1.Mexico pneumonia therapeutics market, by therapeutics
7.2.2.3.2.Mexico pneumonia therapeutics market, by distribution channel
7.2.2.3.3.Mexico pneumonia therapeutics market, by age group

7.2.3.North America market size and forecast, by therapeutics
7.2.4.North America market size and forecast, by distribution channel
7.2.5.North America market size and forecast, by age group

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.UK

7.3.2.1.1.UK pneumonia therapeutics market, by therapeutics
7.3.2.1.2.UK pneumonia therapeutics market, by distribution channel
7.3.2.1.3.UK pneumonia therapeutics market, by age group

7.3.2.2.Germany

7.3.2.2.1.Germany pneumonia therapeutics market, by therapeutics
7.3.2.2.2.Germany pneumonia therapeutics market, by distribution channel
7.3.2.2.3.Germany pneumonia therapeutics market, by age group

7.3.2.3.France

7.3.2.3.1.France pneumonia therapeutics market, by therapeutics
7.3.2.3.2.France pneumonia therapeutics market, by distribution channel
7.3.2.3.3.France pneumonia therapeutics market, by age group

7.3.2.4.Italy

7.3.2.4.1.Italy pneumonia therapeutics market, by therapeutics
7.3.2.4.2.Italy pneumonia therapeutics market, by distribution channel
7.3.2.4.3.Italy pneumonia therapeutics market, by age group

7.3.2.5.Spain

7.3.2.5.1.Spain pneumonia therapeutics market, by therapeutics
7.3.2.5.2.Spain pneumonia therapeutics market, by distribution channel
7.3.2.5.3.Spain pneumonia therapeutics market, by age group

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe pneumonia therapeutics market, by therapeutics
7.3.2.6.2.Rest of Europe pneumonia therapeutics market, by distribution channel
7.3.2.6.3.Rest of Europe pneumonia therapeutics market, by age group

7.3.3.Europe market size and forecast, by therapeutics
7.3.4.Europe market size and forecast, by distribution channel
7.3.5.Europe market size and forecast, by age group

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.India

7.4.2.1.1.India pneumonia therapeutics market, by therapeutics
7.4.2.1.2.India pneumonia therapeutics market, by distribution channel
7.4.2.1.3.India pneumonia therapeutics market, by age group

7.4.2.2.China

7.4.2.2.1.China pneumonia therapeutics market, by therapeutics
7.4.2.2.2.China pneumonia therapeutics market, by distribution channel
7.4.2.2.3.China pneumonia therapeutics market, by age group

7.4.2.3.Japan

7.4.2.3.1.Japan pneumonia therapeutics market, by therapeutics
7.4.2.3.2.Japan pneumonia therapeutics market, by distribution channel
7.4.2.3.3.Japan pneumonia therapeutics market, by age group

7.4.2.4.Australia

7.4.2.4.1.Australia pneumonia therapeutics market, by therapeutics
7.4.2.4.2.Australia pneumonia therapeutics market, by distribution channel
7.4.2.4.3.Australia pneumonia therapeutics market, by age group

7.4.2.5.South Korea

7.4.2.5.1.South Korea pneumonia therapeutics market, by therapeutics
7.4.2.5.2.South Korea pneumonia therapeutics market, by distribution channel
7.4.2.5.3.South Korea pneumonia therapeutics market, by age group

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific pneumonia therapeutics market, by therapeutics
7.4.2.6.2.Rest of Asia-Pacific pneumonia therapeutics market, by distribution channel
7.4.2.6.3.Rest of Asia-Pacific pneumonia therapeutics market, by age group

7.4.3.Asia-Pacific market size and forecast, by therapeutics
7.4.4.Asia-Pacific market size and forecast, by distribution channel
7.4.5.Asia-Pacific market size and forecast, by age group

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil pneumonia therapeutics market, by therapeutics
7.5.2.1.2.Brazil pneumonia therapeutics market, by distribution channel
7.5.2.1.3.Brazil pneumonia therapeutics market, by age group

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia pneumonia therapeutics market, by therapeutics
7.5.2.2.2.Saudi Arabia pneumonia therapeutics market, by distribution channel
7.5.2.2.3.Saudi Arabia pneumonia therapeutics market, by age group

7.5.2.3.South Africa

7.5.2.3.1.South Africa pneumonia therapeutics market, by therapeutics
7.5.2.3.2.South Africa pneumonia therapeutics market, by distribution channel
7.5.2.3.3.South Africa pneumonia therapeutics market, by age group

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA pneumonia therapeutics market, by therapeutics
7.5.2.4.2.Rest of LAMEA pneumonia therapeutics market, by distribution channel
7.5.2.4.3.Rest of LAMEA pneumonia therapeutics market, by age group

7.5.3.LAMEA market size and forecast, by therapeutics
7.5.4.LAMEA market size and forecast, by distribution channel
7.5.5.LAMEA market size and forecast, by age group

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.BAYER AG

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.ELI LILLY & COMPANY

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.GlaxoSmithKline PLC

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.LUPIN PHARMACEUTICALS, INC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.MERCK KGAA

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.NOVARTIS AG

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.PFIZER, INC.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.SANOFI S.A.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.TEVA PHARMACEUTICALS INDUSTRIES LIMITED

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 02.PNEUMONIA THERAPEUTICS MARKET FOR PREVENTION VACCINES, BY REGION, 2020–2030 ($MILLION)
TABLE 03.PNEUMONIA THERAPEUTICS MARKET FOR PREVENTION VACCINES, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 04.PNEUMONIA THERAPEUTICS MARKET FOR TREATMENT DRUGS, BY REGION, 2020-2030 ($MILLION)
TABLE 05.PNEUMONIA THERAPEUTICS MARKET FOR TREATMENT DRUGS, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 06.GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 07.PNEUMONIA THERAPEUTICS MARKET FOR HOSPITALS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 08.PNEUMONIA THERAPEUTICS MARKET FOR PHARMACEUTICAL STORES, BY DISTRIBUTION CHANNEL 2020-2030 ($MILLION)
TABLE 09.PNEUMONIA THERAPEUTICS MARKET, OTHERS, BY DISTRIBUTION CHANNEL 2020-2030 ($MILLION)
TABLE 10.PNEUMONIA THERAPEUTICS MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 11.PNEUMONIA THERAPEUTICS MARKET FOR PEDIATRIC, BY REGION, 2020–2030 ($MILLION)
TABLE 12.PNEUMONIA THERAPEUTICS MARKET FOR ADULT, BY REGION, 2020–2030 ($MILLION)
TABLE 13.PNEUMONIA THERAPEUTICS MARKET FOR GERIATRIC, BY REGION, 2020–2030 ($MILLION)
TABLE 14.PNEUMONIA THERAPEUTICS MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 15.NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 16.U.S. PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 17.U.S. PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 18.U.S. PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 19.CANADA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 20.CANADA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 21.CANADA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 22.MEXICO PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 23.MEXICO PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 24.MEXICO PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 25.NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 26.NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 27.NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 28.EUROPE PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 29.UK PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 30.UK PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 31.UK PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 32.GERMANY PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 33.GERMANY PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 34.GERMANY PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 35.FRANCE PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 36.FRANCE PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 37.FRANCE PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 38.ITALY PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 39.ITALY PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 40.ITALY PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 41.SPAIN PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 42.SPAIN PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 43.SPAIN PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 44.REST OF EUROPE PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 45.REST OF EUROPE PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 46.REST OF EUROPE PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 47.EUROPE PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 48.EUROPE PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 49.EUROPE PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 50.ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 51.INDIA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 52.INDIA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 53.INDIA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 54.CHINA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 55.CHINA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 56.CHINA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 57.JAPAN PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 58.JAPAN PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 59.JAPAN PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 63.SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 64.SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 65.SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 69.ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 70.ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 71.ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 72.LAMEA PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 73.BRAZIL PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 74.BRAZIL PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 75.BRAZIL PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 76.SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 77.SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 78.SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 79.SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 80.SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 81.SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 82.REST OF LAMEA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 83.REST OF LAMEA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 84.REST OF LAMEA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 85.LAMEA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020–2030 ($MILLION)
TABLE 86.LAMEA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 87.LAMEA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 88.ABBOTT: COMPANY SNAPSHOT
TABLE 89.ABBOTT: PRODUCT SEGMENTS
TABLE 90.ABBOTT: PRODUCT PORTFOLIO
TABLE 91.ABBOTT: KEY DEVELOPMENTS
TABLE 92.BAYER: COMPANY SNAPSHOT
TABLE 93.BAYER: OPERATING SEGMENTS
TABLE 94.BAYER: PRODUCT PORTFOLIO
TABLE 95.ELI LILLY & COMPANY: COMPANY SNAPSHOT
TABLE 96.ELI LILLY & COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 97.ELI LILLY & COMPANY: PRODUCT PORTFOLIO
TABLE 98.GLAXO: COMPANY SNAPSHOT
TABLE 99.GLAXO: OPERATING SEGMENTS
TABLE 100.GLAXO: PRODUCT PORTFOLIO
TABLE 101.LUPIN: COMPANY SNAPSHOT
TABLE 102.LUPIN: OPERATING SEGMENTS
TABLE 103.LUPIN: PRODUCT PORTFOLIO
TABLE 104.LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105.MERCK: COMPANY SNAPSHOT
TABLE 106.MERCK: OPERATING SEGMENTS
TABLE 107.MERCK: PRODUCT PORTFOLIO
TABLE 108.MERCK: KEY DEVELOPMENTS
TABLE 109.NOVARTIS: COMPANY SNAPSHOT
TABLE 110.NOVARTIS: OPERATING SEGMENT
TABLE 111.NOVARTIS: PRODUCT PORTFOLIO
TABLE 112.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113.PFIZER: COMPANY SNAPSHOT
TABLE 114.PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 115.PFIZER: PRODUCT PORTFOLIO
TABLE 116.PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117.SANOFI: COMPANY SNAPSHOT
TABLE 118.SANOFI: OPERATING BUSINESS SEGMENTS
TABLE 119.SANOFI: PRODUCT PORTFOLIO
TABLE 120.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 121.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 122.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO

 LIST OF FIGURES

FIGURE 01.PNEUMONIA THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR PREVENTION VACCINES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR TREATMENT DRUGS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR PHARMACEUTICAL STORES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR PEDIATRIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET, ADULT, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET, GERIATRIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.ABBOTT: REVENUE SHARE BY REGION, 2020(%)
FIGURE 24.BAYER: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.BAYER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 27.ELI LILLY & COMPANY: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.ELI LILLY & COMPANY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29.GLAXO:NET SALES,2018-2020 ($MILLION)
FIGURE 30.GLAXO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31.GLAXO: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32.LUPIN: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.LUPIN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 38.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40.PFIZER: NET SALES, 2018–2020 ($MILLION
FIGURE 41.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 43.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45.TEVA PHARMACEUTICALS: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.TEVA PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)

 
 

Pneumonia therapeutics include both preventive methods and treatment medications such as vaccines and drugs. In addition, rise in prevalence of pneumonia of various types such as bacterial, viral, mycoplasma pneumonia would fuel the growth of the market in the coming years. Furthermore, the advent of unknown mutated microbes that are likely to cause pneumonia has boosted the need for research, and is expected to fuel the market growth during the forecast period. Rise in investment for development of medications to cure pneumonia is expected to propel the growth of the industry in the next few years. In addition, the advent of drug-resistant strains has opened newer avenues for the pneumonia therapeutics market.

North America is expected to gain significant shares in 2020, owing to surge in healthcare spending on respiratory diseases. Furthermore, surge in geriatric population and multidrug resistance among adults and children boost the need for novel drugs. This would help the region generate high revenue in the coming years. In addition, Asia-Pacific is anticipated to gain highest market share , owing to rise in the patient population and increase in the spending on the improvement of healthcare infrastructure.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Pneumonia therapeutics are those medications that are used to help manage with the pneumonia causing antigens.

A. Pneumonia therapeutics are used when the healthcare professionals require assistance in aiding the patients with medications or preventive measures for treating and preventing pneumonia.

A. The total value of pneumonia therapeutics market was $12,293.9 million in 2020.

A. The forecast period in the report is from 2021-2030.

A. The market value of pneumonia therapeutics market in 2030 was $25,546.8 million.

A. The base year calculated in the report is 2020.

A. Increased demand for the pneumonia therapeutics for assistance in prevention of pneumonia disease in the population will drive the market over the near future according to the KOLs.

A. The market has drawn the interest of the healthcare industry, owing to increasing prevalence of different types of pneumonia, rise in R&D in pneumonia therapeutics, and growing awareness among healthcare professionals regarding pneumonia therapeutics

A. By therapeutics, preventin vaccines segment holds the maximum market share.

A. The market in Asia-Pacific is expected to register lucrative CAGR of 10.0% and highest revenue over the forecast period owing to presence of large population base, increase in awareness regarding pneumonia therapeutics, and rise in disposable income

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Pneumonia Therapeutics Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers